The RESOLVE Consortium relies on expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients. This affordable, minimally-invasive biomarker aims to guide consolidation therapy intensity, improve quality of life, and reduce costs.
The Project
Welcome to the RESOLVE Project: Optimizing Leukemia Treatment – The RESOLVE Consortium establishes MRD as a key biomarker for guiding AML and CLL treatment. By developing a patient registry, standardizing MRD analysis, and conducting a multinational trial, we strive to improve patient outcomes.
Partners and Collaborators
The RESOLVE Consortium brings together leading partners from multiple disciplines and will be supported by expert groups like ELN-DAVID, ALAN, CLLAN, and EHA-SWG Quality of Life & Symptoms.